Global Market Direct’s pharmaceuticals report, “Affichem - Product Pipeline Review - 2013” provides data on the Affichem’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Affichem’s corporate website, SEC filings, investor presentations and featured press releases, both from Affichem and industry-specific third party sources, put together by Global Markets Direct’s team.
- Affichem - Brief Affichem overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of Affichem human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of Affichem with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Affichem’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products.
Reasons to buy
- Evaluate Affichem’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Affichem in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Affichem’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. - Exploit collaboration and partnership opportunities with Affichem. - Avoid Intellectual Property Rights related issues. - Explore the dormant and discontinued projects of Affichem and identify potential opportunities in those areas.
Table Of Contents
Affichem - Product Pipeline Review - 2013 Table of Contents 2 List of Tables 3 List of Figures 3 Affichem Snapshot 4 Affichem Overview 4 Key Information 4 Key Facts 4 Affichem - Research and Development Overview 5 Key Therapeutic Areas 5 Affichem - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 Affichem - Pipeline Products Glance 9 Affichem - Early Stage Pipeline Products 9 Pre-Clinical Products/Combination Treatment Modalities 9 Discovery Products/Combination Treatment Modalities 10 Affichem - Drug Profiles 11 AF-122 11 Product Description 11 Mechanism of Action 11 RandD Progress 11 AF-130s 12 Product Description 12 Mechanism of Action 12 RandD Progress 12 AF-243 13 Product Description 13 Mechanism of Action 13 RandD Progress 13 AF-250s 14 Product Description 14 Mechanism of Action 14 RandD Progress 14 Affichem - Pipeline Analysis 15 Affichem - Pipeline Products by Therapeutic Class 15 Affichem - Pipeline Products by Route of Administration 16 Affichem - Locations And Subsidiaries 17 Head Office 17 Other Locations and Subsidiaries 17 Appendix 18 Methodology 18 Coverage 18 Secondary Research 18 Primary Research 18 Expert Panel Validation 18 Contact Us 19 Disclaimer 19
List of Tables
Affichem, Key Information 4 Affichem, Key Facts 4 Affichem - Pipeline by Indication, 2013 6 Affichem - Pipeline by Stage of Development, 2013 7 Affichem - Monotherapy Products in Pipeline, 2013 8 Affichem - Pre-Clinical, 2013 9 Affichem - Discovery, 2013 10 Affichem - Pipeline By Therapeutic Class, 2013 15 Affichem - Pipeline By Route of Administration, 2013 16 Affichem, Other Locations 17
List of Figures
Affichem - Pipeline by Indication, 2013 6 Affichem - Pipeline by Stage of Development, 2013 7 Affichem - Monotherapy Products in Pipeline, 2013 8 Affichem - Pipeline By Therapeutic Class, 2013 15 Affichem - Pipeline By Route of Administration, 2013 16